Sema4 Holdings Corp. (SMFR)
$0.3106
Rating:
Recommendation:
-
| Symbol | SMFR |
|---|---|
| Price | $0.3106 |
| Beta | 0.000 |
| Volume Avg. | 2.01M |
| Market Cap | 246.373M |
| Shares () | - |
| 52 Week Range | 0.22-4.09 |
| 1y Target Est | - |
| DCF Unlevered | SMFR DCF -> | |
|---|---|---|
| DCF Levered | SMFR LDCF -> | |
| ROE | -130.96% | Strong Sell |
| ROA | -106.92% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 22.93% | Neutral |
| P/E | - | |
| P/B | 18.97 | Strong Buy |
Latest SMFR news
About
Download (Excel)Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services. It also offers Sema4 Signal that enables and advances precision oncology care, from prevention to treatment to remission; and testing for carrier screening, noninvasive prenatal testing, and newborn screening, as well as hereditary cancer testing. In addition, the company provides COVID-19 testing solutions. Sema4 Holdings Corp. was incorporated in 2020 and is headquartered in Stamford, Connecticut.